Mutations of virus do not stymie research –

[Photo/Agencies]

Known mutations of the novel coronavirus have not affected overall progress of drug and vaccine development, and scientists will keep monitoring the virus's evolution and plan research projects accordingly, senior scientists said on Friday.

This week, Chinese scientists announced that they had discovered that the virus had evolved into two major subtypes, and detected 149 mutation points across its genomes. The L subtype, considered more aggressive, is believed to have been more prevalent during the early stages of the outbreak in Wuhan, Hubei province, than its S subtype ancestor, which is relatively more prevalent now.

Zhou Qi, deputy secretary-general of the Chinese Academy of Sciences, said the virus's mutations require further research, and China is conducting a coordinated research effort to evaluate the virus and develop a vaccine.

"All research is under control," he said. "The mutations that we now know have not affected our drug, antibody or vaccine development. We will keep monitoring the mutations the virus generates and plan related research projects accordingly."

Zheng Zhongwei, director of the Development Center for Medical Science and Technology of the National Health Commission, said China has nine ongoing research projects on vaccine development, and some will hopefully enter clinical trials in April.

The five main types of vaccines that China is working on are an inactivated vaccine, recombinant subunit vaccine, adenoviral vector vaccine, live attenuated vaccine and nucleic acid-based vaccine.

Zheng said he had not seen reports of foreign researchers working on an inactivated vaccine, which consists of virus particles that no longer have disease-producing capability. As for the recombinant and vector vaccines, he said both have moved into animal trials and their progress is on par with that of other countries.

For drug development, China has expanded the use of trial drugs and treatments, including plasma transfusion, artificial extracorporeal liver support often called liver dialysis and traditional Chinese medicine, said Sun Yanrong, deputy director of the China National Center for Biotechnology Development.

Advanced treatments such as stem cell and monoclonal antibody therapies are also being researched as a way to save patients in critical condition, she added. Chloroquine phosphate has moved from trials to clinical treatment, and no obvious side effects were found in the 285 severely ill patients taking the drug.

Scientists have expanded clinical trials for favipiravir a Japanese antiviral drug that showed promise against the virus in clinical trials in Shenzhen, Guangdong province to cover patients in Wuhan.

Doctors from hospitals in Beijing and Harbin, Heilongjiang province, are doing clinical trials for stem cell therapy and preliminary results have found the treatment safe and effective, Sun said, adding that its use will be expanded in Wuhan.

Clinical results for artificial liver support show it can significantly reduce the treatment time for critically ill patients and improve their recovery rate, she said.

Tocilizumab, a drug that suppresses overreactions of the immune system, has recently been added to the latest treatment and diagnosis guideline of the National Health Commission. It helps to inhibit a deadly medical condition called a cytokine storm an overproduction of immune cells that damages healthy tissues which is also one of the main causes of death for critically ill patients.

Sun said around 272 severely ill patients are being treated with Tocilizumab. The patients came from 14 hospitals in Wuhan, Zhou added. Early clinical data showed that 20 severely or critically ill patients had fevers lowered within a day after receiving the drug, and 19 patients had recovered within two weeks.

Contact the writers at zhangzhihao@chinadaily.com.cn

See original here:
Mutations of virus do not stymie research -

Here’s the Real Reason ‘Hawaii Five-0’ Is Getting Cancelled – Country Living

Hawaii Five-0 has been a TV staple since it debuted in 2010. Weve come to know and love Alex OLoughlins McGarrett and Scott Caan as Danno, and we cant imagine a Friday night without the duo.

But were going to have toand very soon. Hawaii Five-0 has officially been cancelled, and the series finale is slated to air in less than a month.

Its never easy to say goodbye to a hit franchise that carried on the legacy of the original with such distinction, while establishing its own signature style, said Kelly Kahl, President of CBS Entertainment. We cannot be prouder of its quality and longevity and are thankful for the passionate fan devotion it inspired.

But if it had such a passionate viewership, then why would CBS end the series? Heres everything we know.

Besides the fact that its been on 10 whole yearsa pretty lengthy amount of timeit seems there were a few behind-the-scenes factors, too. Deadline claimed Alex and Scotts contracts were up at the end of this season, which often jumpstarts an actors exit.

But the outlet also mentioned that Alex suffered a back injury years ago on set, and that he hasnt quite recovered. He reportedly had a stem cell treatment that helped, but he couldnt sign on for another round. CBS allegedly toyed with the idea of replacing Alex, but instead decided it was time to cut the cord.

The worst news out of all of this is that Hawaii Five-0s final episode will run in less than a month. The two-hour series finale will air on April 3, 2020 so we suggest stocking up on tissues now.

Yes! Apparently James Marsters (Victor Hesse), William Sadler (Jack McGarrett), and Mark Dacascos (Wo Fat) will be back to say goodbye. Theres no word on whether Grace Park or Daniel Dae Kim might return for one last time, but considering their exits seemed a little controversial were not sure we see that happening.

Hopefully they tie everything up as well as Criminal Minds did this year!

Hawaii Five-0

Season 1amazon.com

Hawaii Five-0

Season 3amazon.com

Hawaii Five-0

Season 7amazon.com

Hawaii Five-0

Season 10amazon.com

View original post here:
Here's the Real Reason 'Hawaii Five-0' Is Getting Cancelled - Country Living

Ozzy Osbourne banking on stem cells and pilates to get stage-ready – Calgary Herald

Ozzy Osbourne is banking on stem cell treatment and Pilates to help him manage his Parkinsons disease and get back on stage again.

The Paranoid hitmaker has been laid up since badly injuring himself and suffering from pneumonia last year, revealing he had Parkinsons in January and scrapping his U.S. tour last month, to head to Switzerland for treatment.

In a joint interview with U.K. TV show Good Morning Britain, Ozzy and his wife and manager Sharon opened up about the rockers recovery revealing he is undergoing stem cell treatment to lessen the effects of Parkinsons and boost his immune system.

Theres a professor there (Switzerland), Sharon said. He hasnt got a cure for Parkinsons, no one has but what he can do is he can get Ozzys immune system to here (points high), so now, if Ozzy was to catch a cold it would turn into pneumonia.

This professor has come up with a way of doing stem cells where it helps with the pain. He could hopefully get rid of Ozzys pain and then Ozzy will be healthier to deal with the Parkinsons.

The 71-year-old is not the first person in his family to undergo stem cell treatment, as his son Jack flew to Germany to receive similar therapy to help with his multiple sclerosis.

Meanwhile, the former Black Sabbath frontman has also been working hard to get fit again but thinks he will only truly feel himself again when hes back performing.

I exercise as much as I can. Ive got a trainer, I do Pilates, nurses 24/7, but the best medication I can get is being in front of an audience, which is breaking my heart to be honest, he added. I will (perform again). Absolutely. I will be up there. I have to say that. I know youre going to say what will you do if you cant do it again, thats not an option because I will do it.

More here:
Ozzy Osbourne banking on stem cells and pilates to get stage-ready - Calgary Herald

Spinal Muscular Atrophy Treatment Market to Exhibit a Spectacular CAGR of 28.9%; Growing Initiatives by Government Authorities for Pre-Diagnosis to…

Pune, March 03, 2020 (GLOBE NEWSWIRE) -- The global Spinal Muscular Atrophy Treatment Market size is expected to reach USD 14.49 billion by 2026, exhibiting a CAGR of 28.9% during the forecast period. The rising prevalence of rare diseases around the world will fuel demand for SMA treatment in the forthcoming years, which in turn will aid the growth of the market. As per the National Policy for the treatment of rare diseases, globally, around 6000 to 8000 rare diseases are estimated to exist with new rare diseases reported on a regular basis. Furthermore, 80% of all the rare diseases are genetically originated and therefore impact children inexplicably. The survey also revealed that 50% of new cases are in children and are responsible for 35% of deaths before the age of 1 year, 10% between the ages of 1 and 5 years and 12% between 5 and 15 years. Nonetheless, the growing initiatives by government authorities for pre-diagnosis will impact the Spinal Muscular Atrophy Treatment Market share positively during the forecast period, predicts our lead analysts at Fortune Business Insights.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/spinal-muscular-atrophy-treatment-market-100576

According to the report, published by Fortune Business Insights, titled Spinal Muscular Atrophy Treatment Market Size, Share and Global Trend By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Geography Forecast till 2026 the market size stood at USD 1.72 billion. The SMA Treatment Market report executes a PESTEL study and SWOT analysis to reveal the stability, restrictions, openings, and threats in the smart building market. Combined with the market analysis capabilities and knowledge integration with the relevant findings, the report has foretold the robust future growth of the SMA treatment market, and all articulated with geographical and merchandise segments. Moreover, it also shows different procedures and strategies, benefactors and dealers working in the market, explores components convincing market development, generation patterns, and following systems. Additionally, the figures and topics covered in this report are both all-inclusive and reliable for the readers.

Market Driver:

R&D Initiatives by Key Players to Spur Sales Opportunities

The surge in research and development activities for the improvement of therapies and treatment options by key players will aid the Spinal Muscular Atrophy Treatment Market growth during the forecast period. Various drug pipeline for advanced stages of clinical trials by major pharmaceutical companies will augment the healthy growth of the market. For instance, Genentech/Roches pipeline candidate of Risdiplam, which recently received a priority review from the FDA and is expected to receive a decision on approval from the FDA by May 2020. Furthermore, the growing initiatives for pre-diagnosis and positive reimbursement policies will boost the Spinal Muscular Atrophy Treatment Market trends in the foreseeable future. Moreover, the growing awareness regarding pivotal treatment options will create new opportunities for the market.

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/spinal-muscular-atrophy-treatment-market-100576

Market Restraint:

High Cost of Products to Impede Market Expansion

The cost-intensive products and high prices associated with the rare disease therapies will subsequently obstruct the growth of the market. For instance, spinraza is expected to cost US$ 750,000 for the first year and will be repriced at US$ 375,000 after that. Apart from that, Novartis rare gene therapy, Zolgensma will come at a price of US$ 2.1 million for a one-time treatment. The expensive cost of therapies will restrict the adoption of treatment for many patients, which in turn will act as a restraint for the Spinal Muscular Atrophy Treatment Market revenue.

Regional Insight:

Presence of Major Players to Influence Growth in North America

The market in North America stood at USD 854 million in 2018 and is likely to remain dominant during the forecast period. The growth in the region is attributed to the presence of prominent players in the region. The growing awareness regarding the prevalence of rare disease and pre-treatment initiatives will bolster accelerate the Spinal Muscular Atrophy Treatment Market growth in North America.

List of the Major Players Operating in the Global SMA Treatment Market Include:

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/spinal-muscular-atrophy-treatment-market-100576

Detailed Table of Content:

TOC Continued.!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/spinal-muscular-atrophy-treatment-market-100576

Have a Look at Related Reports:

Bone Growth Stimulators Market Size, Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Nonunion and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026

Spinal Cord Stimulation Market Size, Share and Global Trend By Product (Implantable Pulse Generator, Radiofrequency System), Disease Indication (Failed Back Syndrome, Degenerative Disk Disease, Complex Regional Pain Syndrome, Arachnoiditis), End Users (Hospital, Ambulatory Surgical Centers, Specialty Clinics) and Geography Forecast till 2025

Spinal Devices Market Size, Share & Industry Analysis, By Product Type (Fusion Devices (Cervical Devices, Thoracolumbar Devices, Interbody Devices, and Biologics), Non-Fusion Devices (Vertebral Compression Fracture Devices, Artificial Discs, Dynamic Stabilization Devices, and Others), and Stimulation Devices) By Disease Indication (Degenerative Disc Disease, Complex Deformity, Traumas & Fractures, and Others), By End User (Hospitals & Ambulatory Surge

Spinal Fusion Devices Market Size, Share & Industry Analysis, By Product Type (Cervical Devices, Thoracolumbar Devices, Interbody Devices, and Biologics), By Disease Indication (Degenerative Disc Disease, Complex Deformity, Traumas & Fractures, and Others), By End User (Hospitals & Ambulatory Surgery Centers, Specialty Clinics and Others) and Regional Forecast, 2019-2026

Orthopedic Implants Market Size, Share & Industry Analysis, By Product (Joint Reconstruction, Spinal Implants, Trauma Implants, Dental Implants, Orthobiologics, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026

Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026

Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinsons Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2019-2026

Orthodontics Market Size, Share & Industry Analysis, By Product Type [Instruments and Supplies {Fixed (Brackets, Bands & Buccal Tubes, Archwires, and Others), and Removable (Aligners, Retainers, and Others)}], By End User (Hospitals, Dental Clinics, Others) and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/spinal-muscular-atrophy-sma-treatment-market-9626

See original here:
Spinal Muscular Atrophy Treatment Market to Exhibit a Spectacular CAGR of 28.9%; Growing Initiatives by Government Authorities for Pre-Diagnosis to...

Stem cell/oxygen-releasing microparticle enhances erectile function in cavernous nerve injury model. – Physician’s Weekly

Erectile dysfunction caused by damage to the cavernous nerve (CN) is a common complication of radical prostatectomy for patients with localized prostate cancer. Various studies have investigated repair of damaged tissue and prevention of fibrosis in the corpus cavernosum using stem cell therapy. However, stem cell therapy has limitations, including insufficient nutrient and oxygen supply to transplanted stem cells. This study investigated whether stem cell/oxygen-releasing hollow microparticles (HP) were therapeutic effect on therapeutic effects on erectile dysfunction in a rat model of bilateral cavernous nerve injury (BCNI). Therapeutic effects were observed in the BCNI model at 1,2, and 4 weeks post-cavernous nerve injury. Erectile function further improved after treatment with stem cell/oxygen-releasing HP system compared treatment with only stem cells at 4 weeks. Stem cell/oxygen-releasing HP system increased cGMP level and nNOS, eNOS, a-SMA and M3 expression, while decreasing fibrosis and apoptosis in the corpus cavernosum. Our results clearly show that stem cell survival increase around transplanted stem cell/oxygen releasing hybrid system site. Taken together, an oxygen-releasing HP system supported prolonged stem cell survival, sustaining the paracrine effect of the stem cells, and consequently enhancing erectile function. These findings show promise with regard to prolonged stem cell survival in stem cell applications for various diseases and types of tissue damage.

Read the original post:
Stem cell/oxygen-releasing microparticle enhances erectile function in cavernous nerve injury model. - Physician's Weekly

South Setauket native announces $100G donation to Stony Brook University Hospital – GreaterMoriches

Ward Melville High Schoolalum Dave Wolmetz was once again surrounded by his heroes.

Last Thursday, Wolmetz who co-owns Urban Air Lake Grove with his partner Keith Handler invited the people that saved his life from Stony Brook University Cancer Center to his family entertainment facility. There, he presented the staff with a check worth $100,000.

Im inspired by the groundbreaking research at the Stony Brook University Cancer Center, said Wolmetz, who began treatment of Acute lymphocytic leukemia (ALL) in 2018 at Stony Brook University Hospital.

The South Setauket native underwent total body radiation and chemotherapy treatment at Stony Brooks Cancer Center and is currently in the management phase of his treatment.

Im grateful for the stem cell transplant and excellent care I have received at the facility, he said. The cancer center is a well-established resource and essential to the community to focus on important cancer problems.

The donation money hails from the Why Not Us Foundation, a nonprofit that is dedicated to creating real and lasting change in the world by motivating, empowering and preparing todays youth to be tomorrows leaders.

The funds will benefit Stony Brooks CAR T-cell therapy program, which supports Stony Brook scientists working on developing personalized cell therapy to treat blood cancers, such as leukemia.

The donation ceremony was timely, as it was the one-year anniversary of Wolmetzs stem cell transplant at Stony Brook.

With the incredible generosity, we will be able to improve cancer care for Long Islanders and generate other CARs directed toward other major blood cancers, such as leukemia and multiple myeloma, said Dr. Huda Salman, a hematologist at Stony Brook. Dave Wolmetz (blue) with members of the Stony Brook University Hospital (courtesy)

Top: Urban Air Lake Grove founders Dave Wolmetz and Keith Handler presenting the $100,000 check to Stony Brook University Hospital.

Follow this link:
South Setauket native announces $100G donation to Stony Brook University Hospital - GreaterMoriches

Cell Therapy Market 2020 Insights on Growth Drivers, Dynamics, Key Players, Investment Analysis, Business Opportunities and Future Trends – 3rd Watch…

The study report on Global Cell Therapy Market delivers the market revenue predictions for each geographical region. In addition, the Cell Therapy report also offers market insight on growth opportunities, disruptive technologies on the basis of innovative business models, several value-added services, and the competitive background of the market which can increase the market growth. Likewise, the report also contains top predictions of the global Cell Therapy market over the forecast period. The report is designed with the forecast period to anticipate the market size of Cell Therapy industry.

Get Sample PDF Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

The most commonly used process of cell therapy aims to use healthy cells from a donor (Allogeneic) which is compatible or autogenic that is from the patient itself along with their alteration to increase their therapeutic ability. There are various complex steps involved in the process like genetic screening of cell, cell harvesting and reinfusion into the patients body. All these steps are complex and important and have therapeutic result on the patient. These advanced usage of cell therapy will result in growth of the cell therapy market size during the forecast period.

Cell therapy market trends indicate growth owing to the various regulations being approved by the government in the desire to provide quick relief to the patients. Furthermore, many healthcare industries are working in collaboration with the government to identify the various processes to ways to improve cell therapy. Furthermore, the cell therapy market size is also influenced by the commercialization of stem cells treatments.

Browse Complete Report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

The Stem cell therapy segment dominates the types of cell therapy and is said to have the maximum success rate. It has a special feature that it differentiates into any category of cell, at the same time ensuring the individual identity is intact. Industry experts state that the stem cell would revolutionize regenerative medicine, owing to its extensive use in treatment of fatal disease like neurodegenerative, cardiovascular and cancer. The growth of cell therapy market size is also factored to the increased research and development about the same. However, at the same time the huge cost involved in the various processes involved might be hinder the market growth.

The cell therapy market size is segmented on various categories like Clinical-use, Research and Therapy type and region. On the basis of region, North America is projected to contribute the maximum share to the market owing to increased development.

Key players in the market are JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Segmentation:

The various segments of cell therapy market size are:

By Use & Type Outlook

By Cell Therapy Type

By Therapeutic Area

By Therapy Type

By Region

Buy This Report @ https://www.adroitmarketresearch.com/researchreport/purchase/611

About Adroit Market Research:

Adroit Market Research provide quantified B2B research on numerous opportunistic markets, and offer customized research reports, consulting services, and syndicate research reports. We assist our clients to strategize business decisions and attain sustainable growth in their respective domain. Additionally, we support them with their revenue planning, marketing strategies, and assist them to make decisions before the competition so that they remain ahead of the curve.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

Read the original:
Cell Therapy Market 2020 Insights on Growth Drivers, Dynamics, Key Players, Investment Analysis, Business Opportunities and Future Trends - 3rd Watch...

Gilead to Acquire Forty Seven for $4.9 Billion – PharmiWeb.com

Gilead Gains Forty Sevens Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma

Transaction Supports Gileads Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline

FOSTER CITY, Calif.&MENLO PARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.(Nasdaq: GILD) andForty Seven, Inc.(Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for$95.50per share in cash. The transaction, which values Forty Seven at approximately$4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20200302005443/en/

Through the addition of Forty Sevens investigational lead product candidate, magrolimab, the acquisition will strengthen Gileads immuno-oncology research and development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). The investigational therapy targets CD47, a do not eat me signal that allows cancer cells to avoid destruction thereby permitting the patients own innate immune system to engulf and eradicate those cancer cells. Forty Seven presented promising results of a Phase 1b study of magrolimab in patients with MDS and AML at theAmerican Society of Hematologymeeting inDecember 2019. Magrolimab has the potential to be a first-in-class therapy.

This agreement builds on Gileads presence in immuno-oncology and adds significant potential to our clinical pipeline, said Daniel ODay, Chairman and Chief Executive Officer ofGilead Sciences. Magrolimab complements our existing work in hematology, adding a non-cell therapy program that complements Kites pipeline of cell therapies for hematological cancers. With a profile that lends itself to combination therapies, magrolimab could potentially have transformative benefits for a range of tumor types. We are looking forward to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer.

This is an exciting day for patients who may one day benefit from future anti-CD47 therapies and other immuno-oncology treatments based on our research and an exciting time for Forty Seven as this allows us to achieve our vision of helping patients defeat their cancer, commentedMark McCamish, MD, PhD, President and Chief Executive Officer of Forty Seven. We are pleased to join Gilead and believe that by combining our scientific expertise with Gileads strength in developing treatments that modify the immune system, we will be able to more rapidly advance our therapies.

Magrolimab

Forty Seven is initially studying magrolimab in patients with MDS and AML. Additional studies are ongoing in non-Hodgkin lymphoma (NHL) and solid tumors. Magrolimab has been granted Fast Track designation by theU.S. Food and Drug Administration(FDA) for the treatment of MDS and AML, and for the treatment of relapsed or refractory DLBCL and follicular lymphoma, two forms of B-cell NHL. Magrolimab has also been granted Orphan Drug designation by the FDA for the treatment of MDS and AML and by theEuropean Medicines Agencyfor the treatment of AML.

More than 400 patients have received the compound to date through clinical trials.

Ongoing Phase 1b Clinical Trial

InDecember 2019, Forty Seven presented promising results of a Phase 1b trial evaluating magrolimab in combination with azacitidine in untreated patients with higher risk MDS and untreated patients with AML, who are ineligible for induction chemotherapy. This has led to the initiation of a potential registrational cohort in MDS. All patients received a 1 mg/kg priming dose of magrolimab, coupled with intrapatient dose escalation to mitigate on-target anemia. Patients were then treated with full doses of azacitidine and magrolimab maintenance doses of 30 mg/kg weekly.

As of the data cutoff ofNovember 18, 2019, 62 patients had been treated with the combination in the Phase 1b portion of the trial, including 35 patients with MDS and 27 patients with AML.

Clinical Activity Data

As of the data cutoff, 46 patients were evaluable for response assessment, including 24 patients with untreated higher-risk MDS and 22 patients with untreated AML, who were ineligible for induction chemotherapy.

Safety Data

As of the data cutoff, the combination of magrolimab and azacitidine was well-tolerated, with no evidence of increased toxicities compared to azacitidine alone. Adverse events (AEs) were consistent with prior clinical experience. No deaths were observed in the first 60 days on combination treatment and only one patient out of 62 (1.6 percent) discontinued treatment due to a treatment-related AE.

Additional Programs

Beyond magrolimab, Forty Seven is preparing to advance two additional investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP antibody, is being developed for the treatment of cancer, as well as certain non-oncology settings, including transplantation conditioning.

Terms of the Transaction

Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Forty Sevens common stock at a price of$95.50per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer.

Consummation of the tender offer is subject to a minimum tender of at least a majority of outstanding Forty Seven shares plus Forty Seven shares underlying vested options, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

Gilead plans to pay all cash consideration for the transaction. The tender offer is not subject to a financing condition.

Citi and J.P. Morgan are acting as joint financial advisors to Gilead.Centerview Partners LLCis acting as the exclusive financial advisor to Forty Seven.Skadden, Arps, Slate, Meagher & Flom LLPis serving as legal counsel toGileadandCooley LLPis serving as legal counsel to Forty Seven.

Conference Call

At8:00 a.m. Eastern Timetoday, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. A live webcast of the call can be accessed at Gileads Investors page athttp://investors.gilead.com. Please connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download that may be required. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8479332 to access the call.

Telephone replay will be available approximately two hours after the call through8:30 a.m. Eastern Time,March 4, 2020. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 8479332. The webcast will be archived onwww.gilead.comfor one year.

AboutGilead Sciences

Gilead Sciences, Inc.is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters inFoster City, California. For more information onGilead Sciences, please visit the companys website atwww.gilead.com.

About Forty Seven

Forty Seven, Inc.is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed fromStanford University. Forty Sevens lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a dont eat me signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. For more information on Forty Seven, please visit the companys website atwww.fortyseveninc.com.

Original post:
Gilead to Acquire Forty Seven for $4.9 Billion - PharmiWeb.com

Adult Stem Cells: Market 2020 New Innovative Solutions to Boost Global Growth with New Technology, Key Business Strategies, Trend and Forecasts 2024 -…

The Global Adult Stem Cells Market Report Provides A Detailed Analysis of The Current Dynamics of The Market with An Extensive Focus on Secondary Research. It Also Studies the Current Situation of The Market Estimate, Share, Demand, Development Patterns, And Forecast in The Coming Years. The Report Likewise Offers A Total Adult Stem Cells Analysis of Things to Come Patterns and Improvements. It Likewise Examines at The Job of The Main Market Players Engaged with The Business Including Their Adult Stem Cells Corporate Review, Financial Summary and SWOT Analysis.

This Adult Stem Cells Market Report That Is Imagines That the Length of This Market Will Develop during The Time System While the Compound Annual Growth Rate (CAGR) Development. The Adult Stem Cells Business Report Point Would Be the Economic Situations and Relating Orders and Takes the Market Players in Driving Fields Over the World.

GlobalstemJuventas Therapeutics Inc.Epistem Ltd.Hybrid Organ GmbhCellerix SaMesoblast Ltd.Intellicell Biosciences Inc.NeuralstemCelyadCapricor Inc.ClontechCellerant Therapeutics Inc.Cellular Dynamics InternationalBiotime Inc.Beike Biotechnology Co. Ltd.Brainstorm Cell Therapeutics Inc.NeurogenerationInternational Stem Cell Corp.Gamida Cell Ltd.Caladrius Biosciences Inc.Cytori Therapeutics Inc.

Most important types of Adult Stem Cells products covered in this report are:Epithelial stem cellsHematopoietic stem cells

Most widely used downstream fields of Adult Stem Cells market covered in this report are:Neurodegenerative diseasesHeart diseaseBone diseaseOthers

Which prime data figures are included in the Adult Stem Cells market report?

What are the crucial aspects incorporated in the Adult Stem Cells market report?

Who all can be benefitted out of this Adult Stem Cells market report?

Research Goals:

The Report on Global Adult Stem Cells Market Studies the Strategy Pattern Adopted by Prominent International Players. Additionally, The Report Also Evaluates the Market Size in Terms of Revenue (USD MN) For the Forecast Period. All Data and Figures Involving Percentage Shares Splits, And Breakdowns Are Determined Using Secondary Sources and Verified Through Primary Sources.

Contact Us:Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221, IN +919881074592

Original post:
Adult Stem Cells: Market 2020 New Innovative Solutions to Boost Global Growth with New Technology, Key Business Strategies, Trend and Forecasts 2024 -...

Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes – Cambridge Independent

It is the worlds biggest killer and yet we dont fully understand the leading cause behind it.

Cardiovascular diseases claimed an estimated 17.9 million lives in 2016 31 per cent of all deaths around the globe.

And 85 per cent of these were due to heart attacks and stroke, most commonly caused by a blockage of the arteries known as atherosclerosis.

Now an international team led by a Cambridge professor of cardiovascular medicine is competing for a 30million prize from the British Heart Foundation to unravel its secrets.

If they beat the other three shortlisted teams in the charitys Big Beat Challenge, they will create the worlds first 3D map of atherosclerosis at single cell resolution, giving unparalleled insight into this hardening or blocking of the arteries.

Prof Ziad Mallat, of the Department of Medicine at the University of Cambridge, tells the Cambridge Independent:We are excited about the prospect of this. We hope we have assembled the right team.

Atherosclerosis is very debilitating. If it happens in the arteries that supply the brain, it causes stroke. If it happens in the arteries supplying the heart, it causes heart attacks.

It is really common across the world. Every five minutes in the UK there is one heart attack and one stroke.

Why is this having such a huge impact on the quality of life of people? We believe something is not being treated or understood.

Clinicians currently treat the risk factors for the disease, which include high blood cholesterol, high blood pressure and diabetes.

What we dont do is really treat what causes the disease, which is the malfunctioning of the immune system, says Prof Mallat.

When you have high blood pressure or cholesterol, this injures the arteries. Initially, the immune system sends immune cells to the injured vessel to try to heal the artery.

However, what we know is that most of the time the immune system doesnt operate properly and this prevents the healing, and so the disease progresses.

We have good understanding of how this happens in pre-clinical models, like mouse models, but very limited understanding of how it happens in humans.

We think this is what is preventing doctors and scientists from finding a treatment that would transform the way patients are treated.

Through their iMap, as they are calling it, Prof Mallat and the team of global experts he has assembled want to understand what is happening in the accumulations, known as plaques, that block the arteries and affect blood flow to the heart and other parts of the body. The plaques can be made up of fat, cholesterol, calcium and other substances.

These plaques obstruct the lumen [the interior space in the artery] and even burst into the lumen, leading to clot formation, which obstructs the blood flow. This causes the heart attacks and strokes, says Prof Mallat.

Our idea is to build the first 3D map of these fatty plaques, at

. We would like to know what each immune cell and each cell in the vessel wall is doing. What is its genetic make-up? What is its protein make-up? What is the fuel that it is using? Why, when the immune cell comes along to do a good job, does it stop doing it?

We want to interrogate each cell and work out how it is interacting and communicating with other cells.

Only with this 3D map of the plaques will we be able to understand what is happening inside. Once we have done this, we will be able to harness this knowledge to find new protective methodologies and therapies.

These therapies could harness the immune system, which raises the possibility of vaccinating against atherosclerosis.

If we understand how the immune cells react, we can use the information to re-educate them with vaccination, suggests Prof Mallat. If they are overreacting to fat components or protein components, we can educate them to make them do the right job when they see this in the arteries, to reduce the inflammation and limit the development of the disease.

The scale of this challenge, however, is vast and requires a multi-disciplinary approach.

It needs a lot of different expertise around the world, says Prof Mallat. You need good cardiologists, good molecular biologists, immunologists, mathematicians and computer scientists because the information will be huge and needs to be integrated together. You need people who know a lot about genomics, lipidomics and proteomics, so we have gathered world-leading experts in each of these areas to come together and look at this problem from every angle possible.

Among those helping Prof Mallat is Sarah Teichmann, from the Wellcome Sanger Institute at Hinxton, who is the co-founder of the global consortium working on the Human Cell Atlas a hugely ambitious and important project creating comprehensive reference maps of all human cells in the human body.

They are looking at the make-up of healthy organs, notes Prof Mallat. Some of the investigators are mapping some of the arteries and are looking at vascular cells like endothelial cells. It is intriguing but nobody else is looking at other cells in the artery. We are looking at both the healthy arteries and the diseased arteries. It is building on the work of the Human Cell Atlas.

Also on the team are experts from Imperial College London, Germany, France, Spain, the La Jolla Institute of Immunology in San Diego and from Icahn School of Medicine at Mount Sinai in New York.

Key to their work is the need for data and samples, and the group has multiple sources available.

We have organ donors from the Cambridge bio-repository and the clinical school at Mount Sinai, so we have access to healthy and diseased arteries from the same individuals.

We have access to blood from these individuals and to immune cells from other parts of the body, so we can compare what the immune cells are doing in different compartments.

The other source is from a cohort of thousands of individuals, through a collaboration with Professor Valentin Fuster in Madrid, who have been followed for more than 10 years, and they will be followed for another 10 years.

We have blood samples and microbiota from them. We also have access to imaging of their arteries. They are followed for cardiovascular outcomes, so if someone has a heart attack or stroke, it is documented.

We will be able to look at the ageing of the immune system in these individuals and how this correlates to changes in their arteries and the occurrence of disease.

All of this is being done at very high resolution, which has not been done before. Integrating the information from the genes, the proteins, the lipids and so on, to have a broad view, has never been possible.

There are parallels with the work being carried out at Cancer Research UK Cambridge Institute under Prof Greg Hannon, where the first virtual 3D tumour is being created using a multi-disciplinary team.

We are discussing with him how we can integrate some of the technologies he is developing. It will be fantastic to collaborate with him on this, says Prof Mallat.

What is known already is that our arteries are sensitive to changes in blood flow.

Even subtle perturbations in the micro-environment are sensed by the arteries and can be considered as a danger, explains Prof Mallat.

When it interprets this as a danger, it sends signals to the immune system to react. I would say this is happening almost continuously, and is aggravated of course when you have additional stimuli like high blood cholesterol or exposure to smoke.

While the use of imaging and monitoring of biomarkers is helping us diagnose atherosclerosis earlier, Prof Mallat describes this as not optimal, because we dont understand the disease in a comprehensive manner. A 3D map would aid diagnosis, prediction and prevention of disease, as well as opening up new therapeutic avenues.

Nobody knew 10 or 15 years ago that the immune system could play such a huge role in cancer, Prof Mallat points out. Now cancer immunotherapy is advancing enormously. We are convinced that atherosclerosis is highly motivated by the immune system but no-one is targeting the immune system to treat it. Thats why we want to understand it and we think this could really induce a revolution in our understanding and how we treat it.

Cambridge Cardiovascular to host events at Cambridge Science Festival

Visitors to Cambridge Science Festival will have a chance to find out more about the iMap project and the work of cardiovascular researchers.

Cambridge Cardiovascular, an umbrella group for the field, is involved in organising activities once again at this years festival, which runs from March 9 to 22.

At 6-7pm on Wednesday, March 18 at the Mill Lane lecture rooms in Cambridge, a talk titled More than a blocked pipe: The hardening of the arteries and their role in stroke and heart attacks will be delivered by Dr Nick Evans, of the Department of Medicine, and Prof Melinda Duer, of the Department of Chemistry.

At 6-7pm on Friday, March 20, also at Mill Lane lecture rooms, Dr Sanjay Sinha, of Cambridge Stem Cell Instituteand the Department of Medicine will discuss Mending broken hearts: stem cells for heart disease.

Then, from 11am to 4pm on Sunday, March 22, A View of the Heart will be on offer at the Cambridge Academy for Science and Technology, in Long Road, where cardiovascular scientists will help you explore the organ and visualise heartbeats.

Book at sciencefestival.cam.ac.uk.

The Big Beat Challenge

The British Heart Foundations 30million Big Beat Challenge is designed as the charitys moon-shot to propel our understanding of cardiovascular disease into a new era.

Some 75 applications were received from 40 countries following its launch in August 2018, and these have been whittled down to four, including the one led by Prof Mallat to map and treat atherosclerosis. The other ideas are:

Hybrid heart

Led by Jolanda Kluin, professor of translational cardiothoracic surgery at the University of Amsterdam in the Netherlands, this team plans to create a solution for heart failure by developing a soft robotic heart. They intend to design, build, test and implant a hybrid heart that consists of a soft robotic shell forming the soft artificial muscles and sensors to enable natural motion, and a tissue-engineered lining to make sure all the surfaces in contact with blood are safe. With wireless energy transfer, the vision is that this could replace the need for human heart transplantation.

Echoes

Led by Professor Frank Rademakers, chief medical technology officer at University Hospitals Leuven, Belgium, this team would develop wearable technology that can be used in daily life to capture more data than ever before. This information ranging from symptoms and physical activity to heart function and air quality could be used alongside genetic and healthcare data to transform diagnosis, monitoring and treatment of heart and circulatory diseases through the creation of a digital twin.

Cure heart

This project aims to provide a cure for inherited, killer heart muscle diseases. Led by Professor Hugh Watkins, BHF chair of cardiovascular medicine at the University of Oxford, these researchers will develop a treatment that targets and silences the faulty genes responsible for cardiomyopathies diseases of the heart muscle that can lead to sudden death at an early age. They intend to combine a deep understanding of underlying genetic mechanisms with new technologies, to stop the progression of the damage caused by genetic heart muscle diseases, or even reverse the damage.

Professor Sir Nilesh Samani, medical director at the British Heart Foundation, said: Heart and circulatory diseases remain the number one cause of death worldwide.

Were taking small steps forward every year but whats needed is a giant leap, which wont be achieved by a business-as-usual approach.

The Big Beat Challenge embodies our ambition to turbo-charge progress and could lead to its own man on the moon moment. I have absolutely no doubt the winning idea will define the decade in their area.

The teams will prepare their final applications by June 14, with interviews in early September and a decision expected by the end of the year.

Read more

Our guide to the Cambridge Science Festival 2020

Can HIV be cured? Evelyn Trust-funded research at University of Cambridge probes viral latency

Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Sanger Institute scientist helps unveil blueprint for extraordinary Human Cell Atlas

Prof Greg Hannon on taking over at the Cancer Research UK Cambridge Institute and creating the worlds first virtual reality tumour

Read more from the original source:
Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes - Cambridge Independent